PGI21 - COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN’S DISEASE FOR TURKEY
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.863
https://www.valueinhealthjournal.com/article/S1098-3015(18)34165-2/fulltext
Title :
PGI21 - COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN’S DISEASE FOR TURKEY
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)34165-2&doi=10.1016/j.jval.2018.09.863
First page :
Section Title :
Open access? :
No
Section Order :
258